Remdesivir comment watch save

  • FDA APPROVAL DATE: 10/22/2020
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Clinical drug-drug interaction studies have not been performed with remdesivir.
  • PREGNANCY: Insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Investigated for treating COVID-19.

Because transaminase elevations have been reported as a clinical feature of Covid-19, and the incidence was similar in patients receiving placebo versus remdesivir in clinical trials of remdesivir, discerning the contribution of remdesivir to transaminase elevations in patients with Covid-19 can be challenging.

Co-administration of remdesivir with chloroquine phosphate or hydroxychloroquine sulfate is not recommended.

Please login to view the rest of this drug profile.

Page last updated 01/29/2025

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top